Catalent to Debate Logistics of Delivery and Transportation of Cell and Gene Therapies at HPCLC
The panel session, on Wednesday, Oct. 30 at 8:30 a.m., comes at a time when there is an increasing focus on individualizing patient care, and panelists will discuss the critical logistics of delivery and transportation as patient care changes; and as cell, gene and biologics therapies constitute an ever-increasing share of treatments.
SOMERSET, N.J., Oct. 22, 2019 /PRNewswire-PRWeb/ -- Catalent, a global leader in clinical supply services, today announced that Ann McMahon, Program Director, Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel session titled "Cell and Gene Therapy Logistics" at the upcoming Health and Personal Care Logistics Conference (HPCLC), to be held at the Gwen Hotel, Chicago, on Oct. 28-30, 2019.
The panel session, on Wednesday, Oct. 30 at 8:30 a.m., comes at a time when there is an increasing focus on individualizing patient care, and panelists will discuss the critical logistics of delivery and transportation as patient care changes; and as cell, gene and biologics therapies constitute an ever-increasing share of treatments. The panelists will also explore future transportation demands.
Ms. McMahon has over 17 years of experience in the pharmaceutical industry. Prior to joining Catalent, she was Manager, New Product Launch at West-Ward Pharmaceuticals, and also Boehringer Ingelheim. She holds a bachelor's degree in biology/biochemistry from Ohio Northern University, Ada, Ohio; and a master's degree in clinical pharmacology from the Ohio State University, Columbus, Ohio.
For further information, visit https://www.hpclcnet.org/.
To arrange a meeting with Ms. McMahon at the event, contact Richard Kerns at NEPR - [email protected].
About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™
SOURCE Catalent
